<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422899</url>
  </required_header>
  <id_info>
    <org_study_id>AIV007-E01</org_study_id>
    <nct_id>NCT04422899</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreally Administered AIV007 in Subjects With nAMD</brief_title>
  <official_title>A Phase I Study of the Safety, Pharmacokinetics, and Duration of Effect of Intravitreally Administered AIV007 Gel Suspension in Subjects With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AiViva BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AiViva BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety, pharmacokinetics, and duration of effect of intravitreally administered
      AIV007 gel suspension in subjects with neovascular age-related macular degeneration
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>approximately 224 days</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>approximately 224 days</time_frame>
    <description>Number of ETDRS letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central subfield thickness as measured by optical coherence tomography</measure>
    <time_frame>approximately 224 days</time_frame>
    <description>OCT read by a central reading center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to escape medication</measure>
    <time_frame>approximately 224 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AIV007 Treatment Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal, Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV007 Treatment Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal, Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIV007 Treatment Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal, Dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIV007</intervention_name>
    <description>intravitreal</description>
    <arm_group_label>AIV007 Treatment Dose 1</arm_group_label>
    <arm_group_label>AIV007 Treatment Dose 2</arm_group_label>
    <arm_group_label>AIV007 Treatment Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged â‰¥ 50 years

          2. Subjects must provide written informed consent before any study-related procedures are
             performed

          3. Active subfoveal CNV in the study eye secondary to AMD that has previously been
             treated with at least 3 intravitreal injections of an anti-VEGF agent

          4. BCVA in the study eye

               1. Sentinel subjects only: 65 ETDRS letters (20/50 Snellen equivalent) or worse

               2. All other subjects: 78 to 35 ETDRS letters (20/32 to 20/200 Snellen equivalent)

          5. Clear ocular media and adequate pupil dilation in both eyes to permit good quality
             photographic imaging

        Exclusion Criteria:

          1. Previous treatment for nAMD in the study eye, other than standard-of-care anti- VEGF
             IVT injection, eg, cell therapy, brachytherapy, gene therapy

          2. Treatment with anti-VEGF in the non-study eye 2 weeks prior to baseline

          3. Presence of diabetic retinopathy or glaucoma in either eye

          4. Spherical equivalent for refractive error in the study eye of worse than 8.0 diopters
             of myopia (prior to cataract or refractive surgery)

          5. Presence of active infection or inflammation within 30 days prior to screening

          6. Presence of contraindications to anti-VEGF treatment, including myocardial infarction,
             any cardiac event requiring hospitalization, treatment for acute congestive heart
             failure, transient ischemic attack, or stroke within the last 3 months of baseline

          7. Uncontrolled hypertension or diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darlene C Deecher, PhD</last_name>
    <phone>949.662.1949</phone>
    <phone_ext>4</phone_ext>
    <email>office@AiViva.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

